* Leap Therapeutics Inc LPTX.OQ LPTX.O is expected
to show a
fall in quarterly revenue when it reports results on May 12
(estimated).
* The Cambridge Massachusetts-based company is expected to
report
a 48.0% decrease in revenue to $195 thousand from $375 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Leap Therapeutics
Inc is
for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $5, above its last closing price of $1.02.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.12 -0.11 -0.10 Beat 9.1
Sep. 30 2021 -0.10 -0.11 -0.14 Missed -25
Jun. 30 2021 -0.13 -0.12 -0.12 Met 4
Mar. 31 2021 -0.11 -0.11 -0.12 Missed -13.2
Dec. -0.09 -0.09 -0.09 Met -2.3
31 2020
Sep. 30 2020 -0.12 -0.13 -0.09 Beat 29.7
Jun. 30 2020 -0.19 -0.18 -0.12 Beat 33.3
Mar. 31 2020 -0.25 -0.24 -0.25 Missed -2
This summary was machine generated May 10 at 18:33 GMT. All
figures in US dollars unless otherwise stated